Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc., which is headquartered in Vancouver, Canada.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [08/19/2026 13:58 PDT] Achieve Life Sciences, Inc. (NASDAQ:ACHV), Up By 100% ($7.49) From $7.49 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [08/17/2026 07:07 PDT] ACHV Expected to Trade Up After Bullish Patterns Develop
• [07/06/2026 06:49 PDT] ACHV Expected to Trade Down After Bearish Patterns Develop
• [07/02/2026 06:59 PDT] ACHV Expected to Trade Up After Bullish Patterns Develop
• [07/01/2026 10:29 PDT] Achieve Life Sciences, Inc. (NASDAQ:ACHV), Up By 100% ($6.23) From $6.23 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [06/30/2026 16:11 PDT] Achieve Life Sciences, Inc. (NASDAQ:ACHV), Up By 100% ($5.7) From $5.7 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [06/30/2026 07:46 PDT] ACHV Expected to Trade Up After Bullish Patterns Develop
• [06/29/2026 10:29 PDT] Achieve Life Sciences, Inc. (NASDAQ:ACHV), Up By 100% ($5.52) From $5.52 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [06/26/2026 06:35 PDT] ACHV Expected to Trade Up After Bullish Patterns Develop